About
Developing Therapeutics to Treat Undruggable Diseases
ProtOS is an AI-first protein design company developing therapeutics to treat undruggable diseases. Its transformative approach to protein design leverages proprietary AI models to create novel bio-therapeutics that target previously undruggable pathways, by precisely interacting with proteins-of-interest beyond the reach of small molecules and antibodies.
The company has created a robust therapeutic platform to develop Biologic Targeted Protein Degraders. Its SHRED platform uses foundation models to design de-novo AI-proteins that are highly specific and effective in degrading undruggable targets, offering significant advantages over existing PROTAC and Molecular-Glue approaches.
Identity
| Name | ProtOS |
|---|---|
| Slug | protos |
| Type / kind | startup |
| Source _id | sO5BsfNOuJei3kfm1S5XuIfsxmnF0LXNpoWTYML1Y4YgtpKKYv5tJq |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Tel Aviv-Yafo, Israel |
Web & social
| Website | https://www.protos.bio/ |
|---|---|
| https://www.linkedin.com/company/90851603 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMoleculesArtificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
drug-developmentproteinsdisease-management
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}